EICHOR
● Recruiting
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma
Condition: Multiple Myeloma · Sponsor: Janssen Research & Development, LLC
About this study
The primary purpose of this study for Part 1 (Dose Escalation) is to identify the safe effective dose (recommended Phase 2 doses \[RP2Ds\]) and schedule for JNJ-79635322 treatment regimen in combination with daratumumab with or without lenalidomide or with pomalidomide; and for Part 2 (Dose Expansion) is to further characterize the safety and tolerability of JNJ-79635322 combination treatment regimens at selected RP2D(s).
This description comes directly from the study's public registry record.
Talk to the study team
Study Contact · 844-434-4210 · Participate-In-This-Study1@its.jnj.com
Always discuss trial participation with your own doctor first.
Locations (16)
| Colorado Blood Cancer Institute | Denver, Colorado, United States | Recruiting |
| Winship Cancer Institute Emory University | Atlanta, Georgia, United States | Recruiting |
| Monash Medical Centre | Clayton, Australia | Recruiting |
| St Vincents Hospital Melbourne | Fitzroy, Australia | Recruiting |
| Peter MacCallum Cancer Centre | Melbourne, Australia | Recruiting |
| Calvary Mater Newcastle Hospital | Waratah, Australia | Recruiting |
| Wollongong Hospital | Wollongong, Australia | Recruiting |
| Carmel Medical Center | Haifa, Israel | Recruiting |
| Hadassah Medical Center | Jerusalem, Israel | Recruiting |
| Sheba Medical Center | Ramat Gan, Israel | Recruiting |
| Tel Aviv Sourasky Medical Center | Tel Aviv, Israel | Recruiting |
| VU Medisch Centrum | Amsterdam, Netherlands | Recruiting |
+ 4 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06768489